Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 20/20 | 1.00 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 1.00 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | BUB1B | O60566 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceritinib SCHEMBL1014329 | 1.00 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL29349781 | 1.00 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL29810752 | 0.99 | ALK (0.98) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL30053881 | 0.99 | ALK (0.98) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL9936675 | 0.99 | ALK (0.98) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL1545837 | 0.97 | ALK (0.94) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL17879538 | 0.95 | ALK (0.90) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL17879536 | 0.95 | ALK (0.93) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL24852882 | 0.95 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL1014579 | 0.94 | ALK (0.89) | ALKINSRKCNH2PLK4BUB1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602150-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Eyestem Research Private Limited (IN) | 2025-08-20 | — | — | EP | claimed |
| CN-120019141-A | Scalable method for generating Retinal Pigment Epithelial (RPE) cells | 艾视泰研究私人有限公司 | 2025-05-16 | — | — | CN | claimed |
| WO-2024079755-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | claimed |
| WO-2024052931-A1 | A PROTOCOL FOR GENERATING NEURAL PROGENITOR CELLS AND IMPLEMENTATIONS THEREOF | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-03-14 | — | — | WO | claimed |
| CN-110730678-B | Pharmaceutical combination comprising an ALK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727534-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | Burzynski, Stanislaw R. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025238172-A1 | COMBINATIONS OF BRAF AND ALK/TRK INHIBITORS FOR COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| EP-3119423-B1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20220365074-A1 | METHODS AND SYSTEMS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES USING pH | ANALIZA, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4051288-A1 | ALK INHIBITORS FOR TREATMENT OF ALK-NEGATIVE CANCER AND PLASMA CELL-MEDIATED DISEASES | Universitetet I Oslo (NO) | 2022-09-07 | — | — | EP | disclosed |
| CN-114989139-A | Process for preparing pyrimidine-2, 4-diamine dihydrochloride | 诺华股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114901289-A | ALK inhibitors for the treatment of ALK negative cancers and plasma cell mediated diseases | 奥斯陆大学 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022165185-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-110730678-B | Pharmaceutical combination comprising an ALK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022069684-A1 | TREATMENT FOR VIRAL INFECTION | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2022-04-07 | — | — | WO | disclosed |